Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 914-147-1 | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
-Acute oral : The test item is not harmful or toxic by oral route with a LD50> 2000 mg/kg bw. A guideline study (OECD 423) is available in rat.
-Acute dermal : The test item is not harmful or toxic by dermal route with a LD50> 2000 mg/kg bw. A guideline study (OECD 402) is available in rat.
-Acute inhalation: No data is available (Waiving).
Key value for chemical safety assessment
Acute toxicity: via oral route
Link to relevant study records
- Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 07 July 2010 - ............................
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: Compliant to GLP and testing guideline; adequate coherence between data, comments and conclusions.
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 423 (Acute Oral toxicity - Acute Toxic Class Method)
- Deviations:
- yes
- Remarks:
- the animals were not housed individually.
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.1 tris (Acute Oral Toxicity - Acute Toxic Class Method)
- Deviations:
- yes
- Remarks:
- idem above
- GLP compliance:
- yes (incl. QA statement)
- Test type:
- acute toxic class method
- Limit test:
- yes
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Breeder: Janvier, Le Genest-Saint-Isle, France
- Age at study initiation: approximately 8 weeks old
- Weight at study initiation: 198 ± 8 g
- Fasting period before study: 18 hours
- Housing: polycarbonate cages with stainless steel lid, not individually
- Diet (e.g. ad libitum): free access to SSNIFF R/M-H pelleted diet
- Water (e.g. ad libitum): free access to bottles containing tap water (filtered with a 0.22 m filter)
- Acclimation period: at least 5 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 22 +/- 2°C
- Humidity (%): 50 +/- 20%
- Air changes (per hr): 12 cycles/hour
- Photoperiod (hrs dark / hrs light): 12 h/12 h (7:00-19:00)
IN-LIFE DATES: From: 09 July 2010 To: 12 August 2010 - Route of administration:
- oral: gavage
- Vehicle:
- water
- Remarks:
- purified
- Details on oral exposure:
- VEHICLE
- Concentration in vehicle: 30 and 200 mg/mL
- Amount of vehicle (if gavage): 10 mL/kg
- Justification for choice of vehicle: the test item was soluble in purified water at 200 mg/mL
MAXIMUM DOSE VOLUME APPLIED: 10 mL/kg
CLASS METHOD (if applicable)
- Rationale for the selection of the starting dose: As no information on the toxic potential of the test item was available, for animal welfare reasons,
the starting dose-level of 300 mg/kg was chosen. - Doses:
- 300 and 2000 mg/kg.
- No. of animals per sex per dose:
- 3 females per treatment step (300, 2000 and 2000 mg/kg).
- Control animals:
- no
- Details on study design:
- - Duration of observation period following administration: a period of up to 14 days
- Frequency of observations and weighing: each animal was observed after dosing at least once during the first 30 minutes, periodically during the
first 24 hours for detection of possible treatment-related clinical signs and then at least once a day for 14 day.
Type, time of onset and duration of clinical signs were recorded for each animal individually.
The body weight of each animal was recorded just before administration of the test item on day 1 and then on days 8 and 15.
- Necropsy of survivors performed: yes. - Sex:
- female
- Dose descriptor:
- LD50
- Effect level:
- > 2 000 mg/kg bw
- Based on:
- test mat.
- Mortality:
- No mortality was observed during the study.
- Clinical signs:
- other: At the dose-level of 300 mg/kg (three females), no clinical signs were observed. At the dose-level of 2000 mg/kg (three females then confirmation on three other females), ptyalism and loud breathing were noted in one animal within one hour of treatment,
- Gross pathology:
- Macroscopic post-mortem examination of the main organs of the animals revealed no apparent abnormalities.
- Other findings:
- None.
- Interpretation of results:
- not classified
- Remarks:
- Migrated information Criteria used for interpretation of results: other: Regulation EC no.1272/2008
- Conclusions:
- The oral LD50 of the test item, Reaction mass of sodium sulfate, sodium amino-12-dodecanoate and sodium dodecanoedioate (batch No. T710/712), was higher than 2000 mg/kg in rats.
- Executive summary:
The objective of this study was to evaluate the toxicity of the test item, Reaction mass of sodium sulfate, sodium amino-12-dodecanoate and sodium dodecanoedioate, following a single oral administration in rats according to OECD 423 and Commission Regulation (EC) (No. 440/2008, B.1tris, 30 May 2008) guidelines. The study was conducted in compliance with the principles of Good Laboratory Practice Regulations.
Methods
The test item, Reaction mass of sodium sulfate, sodium amino-12-dodecanoate and sodium dodecanoedioate, was administered by oral route (gavage) to groups of three fasted female Sprague-Dawley rats at dose-levels of 300 and 2000 mg/kg under a dosage-volume of 10 mL/kg. The test item was prepared in purified water.
Each animal was observed at least once a day for mortality and clinical signs for a period of up to 14 days following the single administration. Body weight was recorded on day 1 and then on days 8 and 15. On completion of the observation period, the animals were sacrificed then subjected to a macroscopic post-mortem examination.
At necropsy, no apparent abnormalities were observed in any animal.
Results
No mortality was observed during the study. At the dose-level of 300 mg/kg (three females), no clinical signs were observed. When compared to CIT historical control data, the body weight gain of the animals was not affected by treatment with the test item. At the dose-level of 2000 mg/kg (three females then confirmation on three other females), ptyalism and loud breathing were noted in one animal within one hour of treatment, and piloerection was observed in another one 20 minutes after treatment. When compared to CIT historical control data, a lower body weight gain was noted in 1/6 females (vs. 41 ±in control data base) between day 1 and day 8. The body weight gain of this animal returned to normal thereafter.
Conclusion
The oral LD50of the test item, Reaction mass of sodium sulfate, sodium amino-12-dodecanoate and sodium dodecanoedioate (batch No. T710/712), was higher than 2000 mg/kg in rats.
Reference
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- discriminating dose
- Value:
- 2 000 mg/kg bw
Acute toxicity: via dermal route
Link to relevant study records
- Endpoint:
- acute toxicity: dermal
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 07 July 2010 - September 2010
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: Compliant to GLP and testing guideline (the deviation was not considered to have compromised the validity of the study and results); adequate coherence between data, comments and conclusions.
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 402 (Acute Dermal Toxicity)
- Deviations:
- yes
- Remarks:
- all males had a body weight higher than 320 g (up to 355 g)
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.3 (Acute Toxicity (Dermal))
- Deviations:
- yes
- Remarks:
- idem above
- GLP compliance:
- yes (incl. QA statement)
- Test type:
- standard acute method
- Limit test:
- yes
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Breeder: Janvier, Le Genest-Saint-Isle, France
- Age at study initiation: approximately 8 weeks old
- Weight at study initiation: a mean body weight ± standard deviation of 353 ± 2 g for the males and 218 ± 9 g for the females
- Fasting period before study: none
- Housing: polycarbonate cages with stainless steel lid
- Diet (e.g. ad libitum): free access to SSNIFF R/M-H pelleted diet
- Water (e.g. ad libitum):f ree access to bottles containing tap water (filtered with a 0.22 µm filter)
- Acclimation period: at least 5 days before treatment.
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 22 +/- 2°C
- Humidity (%): 50 +/- 20%
- Air changes (per hr): approximately 12 cycles/hour of filtered, non-recycled air
- Photoperiod (hrs dark / hrs light): 12 h / 12 h
IN-LIFE DATES: From: 12 July 2010 To: 27 July 2010. - Type of coverage:
- semiocclusive
- Vehicle:
- unchanged (no vehicle)
- Details on dermal exposure:
- TEST SITE
- Area of exposure: approximately 5 cm x 7 cm for males and 5 cm x 6 cm for females
- % coverage: approximately 10% of the total body surface area of the animals
- Type of wrap if used: a hydrophilic gauze pad held in place with an aerated hypoallergenic.
REMOVAL OF TEST SUBSTANCE
- Washing (if done): on removal of the dressing, any residual test item was removed using a moistened cotton pad
- Time after start of exposure: 24 hours.
TEST MATERIAL
- Amount(s) applied (volume or weight with unit): 2000 mg/kg (1.69 mL/kg) - Duration of exposure:
- 24 hours.
- Doses:
- 2000 mg/kg.
- No. of animals per sex per dose:
- 5 animals per sex and per dose.
- Control animals:
- other: historical control data
- Details on study design:
- - Duration of observation period following administration: 14 days
- Frequency of observations and weighing: each animal was observed frequently during the hours following administration, for detection of possible treatment-related clinical signs then at least once a day for 14 day
- Necropsy of survivors performed: yes. - Sex:
- male/female
- Dose descriptor:
- LD50
- Effect level:
- > 2 000 mg/kg bw
- Based on:
- test mat.
- Mortality:
- None.
- Clinical signs:
- other: Exophthalmos, then corneal opacity, was observed on the left eye of one animal only from day 3 and day 12 to the end of the observation period, respectively. Erythema was noted on two males on days 2 and 3. Erythema was also noted on three, four and five
- Gross pathology:
- Macroscopic post-mortem examination of the main organs of the animals revealed no apparent abnormalities.
- Interpretation of results:
- not classified
- Remarks:
- Migrated information Criteria used for interpretation of results: other: Regulation EC no. 1272/2008
- Conclusions:
- The dermal LD50 of the test item Reaction mass of sodium sulfate, sodium amino-12-dodecanoate and sodium dodecanoedioate
(batch No. T710/712) was higher than 2000 mg/kg in rats. - Executive summary:
The objective of this study was to evaluate the toxicity of the test item, Reaction mass of sodium sulfate, sodium amino-12-dodecanoate and sodium dodecanoedioate (batch No. T710/712), following a single dermal application to rats according to OECD (No. 402, 24th February 1987) and Commission Regulation (EC) (No. 440/2008, Part B.3, 30 May 2008) guidelines .
The study was conducted in compliance with the principles of Good Laboratory Practice Regulations.
Methods
The test item, Reaction mass of sodium sulfate, sodium amino-12-dodecanoate, was applied undiluted for 24 hours to the skin of five male and five female Sprague‑Dawley rats at the dose‑level of 2000 mg/kg, then the test site was covered by a semi‑occlusive dressing.
Each animal was observed at least once a day for mortality and clinical signs for a period of up to 14 days following the single administration. Body weight was recorded on day 1 and then on days 8 and 15.
On completion of the observation period, the animals were sacrificed then subjected to a macroscopic post-mortem examination.
Results
No deaths were observed during the study. Exophthalmos, then corneal opacity, was observed on the left eye of one animal only from day 3 and day 12, respectively, to the end of the observation period.
Erythema was noted on two males on days 2 and 3. Erythema was also noted on three, four and five females on days 2, 3 and 4, respectively. It persisted on these females until day 10 (one female), day 14 (one female) and the end of the observation period (three other females).
A brown discoloration of the skin, was observed in 9/10 animals until day 3, and until day 8 in 1/10 animals. It masked the evaluation of local reactions in one of them until day 3. Scabs were observed from day 4 until the end of the observation period in one female only.
When compared to CIT historical control data, a lower body weight gain was noted between day 1 and day 8 in all males (from 25 to vs. 47 ± in control data base) and 1/5 females (11 g vs. 25 ± in control data base). The body weight gain of these animals returned to normal thereafter.
No apparent abnormalities were observed at necropsy in any animal.
Conclusion
Under the experimental conditions of this study, the dermal LD50of the test item Reaction mass of sodium sulfate, sodium amino-12-dodecanoate and sodium dodecanoedioate (batch No. T710/712) was higher than 2000 mg/kg in rats.
Reference
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- discriminating dose
- Value:
- 2 000 mg/kg bw
Additional information
Acute oral (OECD 423, 2010):
The test item, Reaction mass of sodium sulfate, sodium amino-12-dodecanoate and sodium dodecanoedioate, was administered by oral route (gavage) to groups of three fasted female Sprague-Dawley rats at dose-levels of 300 and 2000 mg/kg under a dosage-volume of 10 mL/kg. The test item was preparedin purified water.
No mortality was observed during the study. At the dose-level of 300 mg/kg (three females), no clinical signs were observed. When compared to CIT historical control data, the body weight gain of the animals was not affected by treatment with the test item.At the dose-level of 2000 mg/kg (three females then confirmation on three other females), ptyalism and loud breathing were noted in one animal within one hour of treatment, and piloerection was observed in another one 20 minutes after treatment. When compared to CIT historical control data, a lower body weight gain was noted in 1/6 females (vs.41 ±in control data base) between day 1 and day 8. The body weight gain of this animal returned to normal thereafter.
At necropsy, no apparent abnormalities were observed in any animal. The oral LD50 of the test item, Reaction mass of sodium sulfate, sodium amino-12-dodecanoate and sodium dodecanoedioate was higher than 2000 mg/kg in rats.
Acute dermal (OECD 402, 2010):
The test item, Reaction mass of sodium sulfate, sodium amino-12-dodecanoate, was applied undiluted for 24 hours to the skin of five male and five female Sprague‑Dawley rats at the dose‑level of 2000 mg/kg, then the test site was covered by a semi‑occlusive dressing.Each animal was observed at least once a day for mortality and clinical signs for a period of up to 14 days following the single administration. Body weight was recorded on day 1 and then on days 8 and 15.On completion of the observation period, the animals were sacrificed then subjected to a macroscopic post-mortem examination.
No deaths were observed during the study. Exophthalmos, then corneal opacity, was observed on the left eye of one animal only from day 3 and day 12, respectively, to the end of the observation period.
Erythema was noted on two males on days 2 and 3. Erythema was also noted on three, four and five females on days 2, 3 and 4, respectively. It persisted on these females until day 10 (one female), day 14 (one female) and the end of the observation period (three other females).
A brown discoloration of the skin, was observed in 9/10 animals until day 3, and until day 8 in 1/10 animals. It masked the evaluation of local reactions in one of them until day 3. Scabs were observed from day 4 until the end of the observation period in one female only.
When compared to CIT historical control data, a lower body weight gain was noted between day 1 and day 8 in all males (from 25 tovs. 47 ± in control data base) and 1/5 females (11 g vs. 25 ± in control data base). The body weight gain of these animals returned to normal thereafter.
No apparent abnormalities were observed at necropsy in any animal.
Under the experimental conditions of this study, the dermal LD50of the test item was higher than 2000 mg/kg in rats.
Justification for classification or non-classification
Acute oral:
According to EU Directive 67/584/EEC and EU regulation (EC) No 1272/2008 (CLP), the Reaction mass of sodium sulfate, sodium amino-12-dodecanoate and sodium dodecanoedioate is not classified for acute oral toxicity.
Justification : LD 50> 2000 mg/kg bw
Acute dermal:
According to EU Directive 67/584/EEC and EU regulation (EC) No 1272/2008 (CLP), the Reaction mass of sodium sulfate, sodium amino-12-dodecanoate and sodium dodecanoedioate is not classified for acute dermal toxicity.
Justification : LD 0> 2000 mg/kg bw
Acute inhalation:
There are no data therefore, the Reaction mass of sodium sulfate, sodium amino-12-dodecanoate and sodium dodecanoedioate is not classified for acute inhalation toxicity.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.